semaglutide trial safety events
Weight Loss Data Scientists Warn About Prescription Weight Loss Headlines
In SURMOUNT-3, 73% of tirzepatide users reported an adverse event, yet only 5.9% experienced serious events, so the headline that tirzepatide loses on safety is misleading. Media summaries often collapse all treatment-emergent adverse events into one figure, ignoring the clinical difference between a fleeting nausea episode and a life-threatening